Altace Will See Challenge From Generic ACE Inhibitors, Not Class Labeling, King Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased attention to benefits of antihypertensives will help Altace and the entire class, King says. “We just have to fight the...battle” on differentiation, CEO Markison says.